AVI BioPharma, Inc. Completes Registered Direct Offering, Raises $20.3 Million
December 19 2007 - 4:05PM
Business Wire
AVI BioPharma, Inc. (NASDAQ: AVII) has successfully completed its
previously announced registered direct offering consistent with the
terms and conditions announced in AVI BioPharma�s December 12, 2007
press release. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any
sale of the securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. The shares of common stock may only be offered by
means of a prospectus. Copies of the final prospectus supplement
and accompanying base prospectus can be obtained from the SEC�s
website at http://www.sec.gov or from Citigroup Global Markets
Inc., 388 Greenwich Street, New York, New York 10013 800-831-9146.
About AVI BioPharma AVI BioPharma develops therapeutic products for
the treatment of life-threatening diseases using third-generation
NeuGene antisense drugs and ESPRIT exon skipping technology. AVI's
ESPRIT technology is initially being applied to potential
treatments for Duchenne muscular dystrophy. AVI's NeuGene compounds
are also designed to treat cardiovascular restenosis, and aid in
Coronary Artery Bypass Graft (CABG) procedures. In addition to
targeting specific genes in the body, AVI's antiviral program uses
NeuGene antisense compounds to combat disease by targeting
single-stranded RNA viruses, including Marburg virus, Ebola Zaire
virus, and H5N1 avian influenza virus. More information about AVI
is available on the company's Web site at www.avibio.com. �Safe
Harbor� Statement under the Private Securities Litigation Reform
Act of 1995: The statements that are not historical facts contained
in this release are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the results of
research and development efforts, the results of preclinical and
clinical testing, the effect of regulation by the FDA and other
agencies, the impact of competitive products, product development,
commercialization and technological difficulties, and other risks
detailed in the company�s Securities and Exchange Commission
filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024